cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/kfh-bm0-tl9
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/w3n-lwp-0tf
title: Nonion politum (d'Orbigny in Fornasini, 1902)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/1vz-2wv-331
title: Globigerinoides ruber (d'Orbigny, 1839)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/tlt-tbb-xjb
title: †Hantkenina liebusi Shokhina, 1937

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/tyh-m74-hqx
title: Hastigerina Thomson in Murray, 1876

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/c0e-kjc-yqz
title: †Fusulinidae Möller, 1878

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/kjr-dsc-4gr
title: †Lepidocyclina Gümbel, 1870

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/4gc-vxp-hss
title: Cidaris Leske, 1778

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/y73-j9f-r24
title: Tubastraea coccinea Lesson, 1830

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/b3m-lea-8tf
title: Animalia

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/q6y-5pc-4m5
title: Foraminifera d'Orbigny, 1826

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.15468/dl.t86yb6
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Chromolaena odorata",
 "Country is Mozambique",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023806-250811113504898/datasets/export for details.
DOI: 10.3535/lhy-kr2-aqy
title: Foraminifera d'Orbigny, 1826

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/rkv-30s-924
title: †Sulcoperculina Thalmann, 1939

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/ms9-qne-ad1
title: Elphidium crispum (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/sjv-3yg-rl3
title: †Gyroidinoides pontoni Brotzen, 1948

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/vsq-g0a-169
title: Bos taurus Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/5aa-th6-7a3
title: †Lepidocyclina Gümbel, 1870

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/zbv-eyg-y0n
title: Nodosaria Lamarck, 1816

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.15468/dl.76sge6
title: Occurrence Download

description: A dataset containing 9 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Chromolaena odorata",
 "Country is Myanmar",
 "HasCoordinate is true"
 ]
}

 The dataset includes 9 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023807-250811113504898/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/8ys-x7g-x7p
title: Foraminifera d'Orbigny, 1826

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/sds-dqn-ev2
title: †Orbitoides faujasii (Defrance, 1823)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/j9g-zw6-7yl
title: †Gryphaea Lamarck, 1801

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.6084/m9.figshare.28512572
title: TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases

description: Breast cancer (BC) is the most common cause of leptomeningeal disease (LMD) and the second most common cause of brain metastases (BMs) among all solid malignancies. Both BMs and LMD are associated with high morbidity and mortality and treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate combining a HER2-targeting antibody with a topoisomerase I inhibitor, has shown activity in HER2-positive (HER2[+]) and HER2-low tumors in both preclinical and clinical settings. Similarly, T-DXd has shown efficacy in HER2[+] BC patients with central nervous system (CNS) involvement. However, data on activity in HER2-low BC patients with BMs and/or LMD using T-DXd are limited. TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II trial (NCT06048718) that will recruit a total of 27 adult patients (13 in the first stage, and 14 in second stage depending on responses in the first stage) to evaluate T-DXd in the HER2-low metastatic BC population presenting with newly diagnosed or progressing BM with or without type II LMD. NCT06048718 (clinicaltrials.gov); 2023 -506,702-39–00 (EudraCT number). Breast cancer cells often spread to the brain (brain metastases) or the membranes surrounding the brain and spinal cord (leptomeningeal disease). Therapies to treat these serious conditions are limited. Trastuzumab deruxtecan (T-DXd), which targets a protein called HER2 (found on the surface of breast cells to control their growth) and includes a powerful anti-cancer component to kill the tumor cells, has shown clinically meaningful results in both HER2-positive (high concentration of HER2 proteins) and HER2-low (low concentration of HER2 proteins) breast cancers. Interestingly, T-DXd has successfully worked in HER2-positive breast cancer patients with brain metastases and/or leptomeningeal disease, but results in their HER2-low counterparts are limited. TUXEDO-4 is a medical study to evaluate the effectiveness of T-DXd in HER2-low breast cancer patients with recently diagnosed or worsening brain metastases, with or without aggressive leptomeningeal disease. The study is taking place in Austria and Spain, and will recruit 27 adult patients. TUXEDO-4 trial TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II clinical trial evaluating the efficacy of trastuzumab-deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) patients presenting with newly diagnosed or progressing brain metastases (BMs), with or without type II leptomeningeal disease (LMD). TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II clinical trial evaluating the efficacy of trastuzumab-deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) patients presenting with newly diagnosed or progressing brain metastases (BMs), with or without type II leptomeningeal disease (LMD).
DOI: 10.6084/m9.figshare.28512572.v1
title: TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases

description: Breast cancer (BC) is the most common cause of leptomeningeal disease (LMD) and the second most common cause of brain metastases (BMs) among all solid malignancies. Both BMs and LMD are associated with high morbidity and mortality and treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate combining a HER2-targeting antibody with a topoisomerase I inhibitor, has shown activity in HER2-positive (HER2[+]) and HER2-low tumors in both preclinical and clinical settings. Similarly, T-DXd has shown efficacy in HER2[+] BC patients with central nervous system (CNS) involvement. However, data on activity in HER2-low BC patients with BMs and/or LMD using T-DXd are limited. TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II trial (NCT06048718) that will recruit a total of 27 adult patients (13 in the first stage, and 14 in second stage depending on responses in the first stage) to evaluate T-DXd in the HER2-low metastatic BC population presenting with newly diagnosed or progressing BM with or without type II LMD. NCT06048718 (clinicaltrials.gov); 2023 -506,702-39–00 (EudraCT number). Breast cancer cells often spread to the brain (brain metastases) or the membranes surrounding the brain and spinal cord (leptomeningeal disease). Therapies to treat these serious conditions are limited. Trastuzumab deruxtecan (T-DXd), which targets a protein called HER2 (found on the surface of breast cells to control their growth) and includes a powerful anti-cancer component to kill the tumor cells, has shown clinically meaningful results in both HER2-positive (high concentration of HER2 proteins) and HER2-low (low concentration of HER2 proteins) breast cancers. Interestingly, T-DXd has successfully worked in HER2-positive breast cancer patients with brain metastases and/or leptomeningeal disease, but results in their HER2-low counterparts are limited. TUXEDO-4 is a medical study to evaluate the effectiveness of T-DXd in HER2-low breast cancer patients with recently diagnosed or worsening brain metastases, with or without aggressive leptomeningeal disease. The study is taking place in Austria and Spain, and will recruit 27 adult patients. TUXEDO-4 trial TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II clinical trial evaluating the efficacy of trastuzumab-deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) patients presenting with newly diagnosed or progressing brain metastases (BMs), with or without type II leptomeningeal disease (LMD). TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II clinical trial evaluating the efficacy of trastuzumab-deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) patients presenting with newly diagnosed or progressing brain metastases (BMs), with or without type II leptomeningeal disease (LMD).
DOI: 10.6084/m9.figshare.28733291
title: Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis

description: This systematic literature review summarizes the real-world effectiveness, safety, and tolerability of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC). Database searches (MEDLINE, Embase, Cochrane) and manual gray literature searches of real-world studies published from 01/01/2020–31/01/2024 were performed. Pooled 12-month overall survival (OS) and progression-free survival (PFS) rates were synthesized by meta-analysis. Across 45 unique studies including &gt;2,600 patients, median OS and PFS were 21.3 and 7.0 months, respectively. In the meta-analysis, 12-month OS and PFS rates (95% CI) from avelumab 1LM start were 69% (65–73%) and 39% (35–44%), respectively. This study supports the established clinical benefit of avelumab 1LM across a broad range of patients with la/mUC in routine practice. Bladder cancer is called advanced when it has spread outside of the urinary tract. People with advanced bladder cancer can be treated with chemotherapy followed by maintenance treatment with a drug called avelumab if their cancer has not gotten worse (i.e. not progressed) after chemotherapy. Maintenance treatment is given to people to slow down or stop the growth of the cancer. In this study, the researchers looked at real‑world evidence in people with advanced bladder cancer who received avelumab maintenance after chemotherapy. Real‑world evidence refers to information about a disease or drug that is gathered outside of clinical trials. Real-world evidence allows researchers to assess whether the outcomes and side effects of treatments seen in controlled clinical trials are similar in routine clinical practice. The researchers conducted a review of published real-world evidence and found 45 studies that included more than 2,600 people with advanced bladder cancer who were treated with avelumab maintenance after chemotherapy. The researchers found that people who received avelumab maintenance in real-world studies experienced similar benefits to people who received avelumab maintenance in clinical trials, including survival benefits, slower cancer progression, and comparable side effects. These results could increase confidence in using avelumab maintenance treatment following chemotherapy among doctors, decision-makers, researchers, and people with advanced bladder cancer and their caregivers, despite the availability of newer treatments. More real-world evidence is needed to investigate the most effective treatments for people with advanced bladder cancer. A PDF version of this infographic is available as supplemental material.
DOI: 10.6084/m9.figshare.28733291.v1
title: Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis

description: This systematic literature review summarizes the real-world effectiveness, safety, and tolerability of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC). Database searches (MEDLINE, Embase, Cochrane) and manual gray literature searches of real-world studies published from 01/01/2020–31/01/2024 were performed. Pooled 12-month overall survival (OS) and progression-free survival (PFS) rates were synthesized by meta-analysis. Across 45 unique studies including &gt;2,600 patients, median OS and PFS were 21.3 and 7.0 months, respectively. In the meta-analysis, 12-month OS and PFS rates (95% CI) from avelumab 1LM start were 69% (65–73%) and 39% (35–44%), respectively. This study supports the established clinical benefit of avelumab 1LM across a broad range of patients with la/mUC in routine practice. Bladder cancer is called advanced when it has spread outside of the urinary tract. People with advanced bladder cancer can be treated with chemotherapy followed by maintenance treatment with a drug called avelumab if their cancer has not gotten worse (i.e. not progressed) after chemotherapy. Maintenance treatment is given to people to slow down or stop the growth of the cancer. In this study, the researchers looked at real‑world evidence in people with advanced bladder cancer who received avelumab maintenance after chemotherapy. Real‑world evidence refers to information about a disease or drug that is gathered outside of clinical trials. Real-world evidence allows researchers to assess whether the outcomes and side effects of treatments seen in controlled clinical trials are similar in routine clinical practice. The researchers conducted a review of published real-world evidence and found 45 studies that included more than 2,600 people with advanced bladder cancer who were treated with avelumab maintenance after chemotherapy. The researchers found that people who received avelumab maintenance in real-world studies experienced similar benefits to people who received avelumab maintenance in clinical trials, including survival benefits, slower cancer progression, and comparable side effects. These results could increase confidence in using avelumab maintenance treatment following chemotherapy among doctors, decision-makers, researchers, and people with advanced bladder cancer and their caregivers, despite the availability of newer treatments. More real-world evidence is needed to investigate the most effective treatments for people with advanced bladder cancer. A PDF version of this infographic is available as supplemental material.
DOI: 10.15468/dl.5hf3rt
title: Occurrence Download

description: A dataset containing 60779 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pistacia terebinthus",
 "HasCoordinate is true"
 ]
}

 The dataset includes 60779 records from 389 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0029034-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.57760/sciencedb.25285
title: SDG Classifications
title: SDG Classifications

description: Excerpts extracted from Thai companies' sustainability reports 2023 with SDG classifications done by a panel of SDG. There are 39 samples with multi-label classification across 17 SDGs.Each row contains an excerpt with related SDGs identified by experts. If the SDG is marked as T," meaning that it is a relevant SDG, F means not relevant, O means it is possible to classified as the SDG but not neccesary.
description: Excerpts extracted from Thai companies' sustainability reports 2023 with SDG classifications done by a panel of SDG. There are 39 samples with multi-label classification across 17 SDGs.Each row contains an excerpt with related SDGs identified by experts. If the SDG is marked as T," meaning that it is a relevant SDG, F means not relevant, O means it is possible to classified as the SDG but not neccesary.
DOI: 10.57760/sciencedb.25299
title: Application of Reinforced U-shaped Suture Technique in Laparoscopic Distal Pancreatectomy: An Analysis of 165 Consecutive Cases
title: Application of Reinforced U-shaped Suture Technique in Laparoscopic Distal Pancreatectomy: An Analysis of 165 Consecutive Cases

description: This study collected data from 165 patients who underwent LDP at the Department of Biliary and Pancreatic Surgery, First Hospital of Shanxi Medical University, between 2018 and February 2025. The inclusion criteria are patients who underwent LDP for various reasons and have complete clinical data. The corresponding exclusion criteria include patients who did not receive further reinforcement of the remnant and those who lack necessary clinical data that could influence the diagnosis of POPF. Patients were divided into two groups according to the method of pancreatic stump suture reinforcement: Group A: non reinforced U-shaped suture with 113 patients; Group B: reinforced U-shaped suture with 52 patients. The collected data covered three aspects: preoperative, intraoperative, and postoperative. Preoperative data: age, gender, body mass index (BMI), smoking history, drinking history, past medical history (such as diabetes and hypertension), ASA anesthesia classification. Intraoperative data: operation time, intraoperative blood loss, and spleen preservation status. Postoperative data: amylase levels in abdominal drainage fluid on postoperative day 3 and beyond, postoperative treatment and care measures and occurrence, type, and severity of postoperative complications . 
description: This study collected data from 165 patients who underwent LDP at the Department of Biliary and Pancreatic Surgery, First Hospital of Shanxi Medical University, between 2018 and February 2025. The inclusion criteria are patients who underwent LDP for various reasons and have complete clinical data. The corresponding exclusion criteria include patients who did not receive further reinforcement of the remnant and those who lack necessary clinical data that could influence the diagnosis of POPF. Patients were divided into two groups according to the method of pancreatic stump suture reinforcement: Group A: non reinforced U-shaped suture with 113 patients; Group B: reinforced U-shaped suture with 52 patients. The collected data covered three aspects: preoperative, intraoperative, and postoperative. Preoperative data: age, gender, body mass index (BMI), smoking history, drinking history, past medical history (such as diabetes and hypertension), ASA anesthesia classification. Intraoperative data: operation time, intraoperative blood loss, and spleen preservation status. Postoperative data: amylase levels in abdominal drainage fluid on postoperative day 3 and beyond, postoperative treatment and care measures and occurrence, type, and severity of postoperative complications .
DOI: 10.15468/dl.4dvk3p
title: Occurrence Download

description: A dataset containing 38332 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Somateria spectabilis (Linnaeus, 1758)",
 "HasCoordinate is true",
 "Year is greater than 1989",
 "Year is less than 2026",
 {
 "not" : {
 "OccurrenceStatus" : [
 "is Absent"
 ]
 }
 },
 "CoordinateUncertaintyInMeters is less than or equal to 1000"
 ]
}

 The dataset includes 38332 records from 27 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006118-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wpat5s
title: Occurrence Download

description: A dataset containing 1148 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((88 31,103 31,103 38,88 38,88 31))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Gypaetus barbatus (Linnaeus, 1758)"
 ]
}

 The dataset includes 1148 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006120-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.p7ubs2
title: Occurrence Download

description: A dataset containing 544 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Hydrangea macrophylla (Thunb.) Ser.",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is Japan"
 ]
}

 The dataset includes 544 records from 43 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006119-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.x24rh9
title: Occurrence Download

description: A dataset containing 1990 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Hydrangea hirta (Thunb.) Siebold",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is Japan"
 ]
}

 The dataset includes 1990 records from 55 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006121-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rrxfey
title: Occurrence Download

description: A dataset containing 2400 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Zelkova serrata (Thunb.) Makino",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is Japan"
 ]
}

 The dataset includes 2400 records from 65 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006123-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.z6n9dr
title: Occurrence Download

description: A dataset containing 773 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-127.71239 -23.00610,-25.28761 -23.00610,-25.28761 18.00610,-127.71239 18.00610,-127.71239 -23.00610))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Coccoloba obovata Kunth"
 ]
}

 The dataset includes 773 records from 62 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006125-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.